Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCLAIM-CTA study of lepodisiran for coronary plaque burden in adults with elevated lipoprotein(a)
NL-OMON61422Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of lepodisiran in atherosclerotic disease, coronary arteriosclerosis and lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Eli Lilly and Company. Primary endpoint: Percent change from baseline in noncalcified plaque volume. Started Oct 2026; status: recruiting.
02
Drugs
lepodisiran
03
Conditions
atherosclerotic diseasecoronary arteriosclerosislipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON61422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61422.